Observational studyBMC nephrology2025
Posttransplant diabetes mellitus (PTDM) frequency, risk factors, and outcomes: a single-center experience.
Observational study in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical consequences and risk factors for posttransplant diabetes mellitus (PTDM) remain underexplored, particularly in the Pakistani population. This study aimed to assess the frequency of PTDM, identify its risk factors, and compare clinical outcomes with those of non-PTDM patients in a single center. METHODOLOGY: A retrospective cohort observational study was conducted on 121 kidney transplant recipients aged 18 years or older from January 2018 to December 2021. Data were collected on demographic characteristics, pretransplant risk factors, and posttransplant outcomes at 3, 6, and 12 months. PTDM was diagnosed via international consensus guidelines, and clinical outcomes were compared between the PTDM and non-PTDM groups.
resultsOut of 492 transplant recipients, a total of 121 participants were included in the study; the mean age was 36.45 ± 10.56 years, the mean BMI was 27.65 ± 5.01 kg/m², and the pretransplant mean FBS was 84.32 ± 12.22 mg/dl. Predominantly, there were males (84.3%), mostly with hypertension as the primary diagnosis (86%). PTDM developed in 27.3% (n = 33) of the participants. PTDM patients had significantly higher fasting blood sugar (FBS) levels (p < 0.0001) and worse outcomes, including higher rates of infection (27.27% vs. 3.41%, p < 0.05), delayed graft function (15.15% vs. 0%, p < 0.05), and transplant rejection (12.12% vs. 1.14%, p < 0.05). Dyslipidemia was also more prevalent in the PTDM group than in the control group at 3, 6, and 12 months.
conclusionPTDM significantly impacts posttransplant outcomes, necessitating careful management to mitigate adverse events such as infection, graft dysfunction, and dyslipidemia. Early detection and targeted interventions may improve clinical outcomes in PTDM patients. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.